Luye Pharma Group Ltd. (HKG:2186)

Market Cap	9.63B +6.2%
Revenue (ttm)	6.76B -2.3%
Net Income	434.95M -48.5%
EPS	0.12 -48.5%
Shares Out	3.99B
PE Ratio	20.85
Forward PE	11.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,368,000
Average Volume	17,771,321
Open	2.320
Previous Close	2.310
Day's Range	2.300 - 2.430
52-Week Range	1.670 - 4.490
Beta	1.00
RSI	44.07
Earnings Date	Mar 30, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,115
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2186

Financial Performance

In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.

Financial numbers in CNY